Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30391792 | 1.00 | AHR (0.45) | AHRCYP2A6NR4A2TNFRIPK1 | |
| SCHEMBL2537652 | 0.80 | AHR (0.50) | AHRTNFRIPK1GPR84SLC6A2 | |
| SCHEMBL8995163 | 0.78 | AHR (0.48) | AHRCYP2A6NR4A2TNFRIPK1 | |
| SCHEMBL26389475 | 0.77 | AHR (0.47) | AHRCYP2A6NR4A2TNFRIPK1 | |
| SCHEMBL794596 | 0.77 | TNF (0.44) | AHRTNFRIPK1GPR84CSNK2A1 | |
| SCHEMBL3584001 | 0.75 | AHR (0.45) | AHRCYP2A6NR4A2TNFRIPK1 | |
| SCHEMBL2380876 | 0.75 | AHR (0.45) | AHRCYP2A6NR4A2TNFRIPK1 | |
| SCHEMBL28783304 | 0.75 | AHR (0.45) | AHRCYP2A6NR4A2TNFRIPK1 | |
| SCHEMBL564695 | 0.75 | AHR (0.50) | AHRCYP2A6NR4A2TNFRIPK1 | |
| SCHEMBL3961345 | 0.75 | TNF (0.42) | AHRTNFRIPK1GPR84SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805664-B | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-114805664-A | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114292582-B | Hyperbranched coating suitable for marine concrete, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114292582-A | Hyperbranched coating suitable for marine concrete, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| WO-2026086928-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2026-04-30 | — | — | WO | disclosed |
| EP-4703359-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| CN-119161324-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024182788-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-118515663-A | Imidazopyridine or imidazopyrazine compounds, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240262838-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20090099236-A1 | 3-Amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | disclosed |
| CN-101316818-A | 3-amino-1-arylpropyl indoles and aza-substituted indoles | HOFFMANN LA ROCHE (CH) | 2008-12-03 | — | — | CN | disclosed |
| US-7446118-B2 | 3-amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1960355-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AND AZA-SUBSTITUTED INDOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008019971-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
| WO-2007062996-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AND AZA-SUBSTITUTED INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | IDO1, RB1, AHR | AHR 3/4885CYP2A6 74/4885NR4A2 366/4885 |
| US-20090099236-A1 | 3-Amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | IDO1, RB1, AHR | AHR 3/4885CYP2A6 74/4885NR4A2 366/4885 |
| US-20240262838-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | NPR1, NPR3, NUCB2 | AHR 88/4885CYP2A6 864/4885NR4A2 29/4885 |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | CYP3A7, CYP3A5, HTR7 | AHR 6/4885CYP2A6 129/4885NR4A2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.